Lixisenatid: Új, döntoen prandialis hatású GLP-1-receptor-agonista készítmény a 2-es típusú diabetes kezelésében

Translated title of the contribution: Lixisenatide: A new GLP-1-receptor agonist with mainly prandial effect for the treatment of patients with type 2 diabetes

Research output: Contribution to journalArticle

Abstract

Recently, lixisenatide, a new incretin mimetic GLP-1-receptor agonist with a mainly prandial effect has been registered for the treatment of patients with type 2 diabetes mellitus. The amino acid sequence of lixisenatide and that of human native GLP-1 is 50% identical. Due to its altered amino acid sequence and conformation, lixisenatide is resistant to inactivation by DPP-4. Lixisenatide is a specific agonist of GLP-1-receptors and its binding has a pharmacologic GLP-1-agonist effect. Lixisenatide is used subcutaneously, its normal daily dose is 1×20 μg. It is mostly used in combination with metformin, but it can be also used to supplement sulfanylurea or basal insulin therapy. Clinical efficiency of lixisenatide has been investigated in the phase-III GetGoal trials. In these trials, adequate glycaemic control and a marked decrease in postprandial blood glucose values were observed. During lixisenatide therapy, a decrease in body weight and no substantial increase in the risk of hypoglycaemia were observed, whereas transient gastrointestinal side effects might occur after initiation of treatment. Lixisenatide as an add-on treatment to basal insulin should be considered as a new treatment approach in the management of type 2 diabetes.

Original languageHungarian
Pages (from-to)413-419
Number of pages7
JournalLege Artis Medicinae
Volume23
Issue number9
Publication statusPublished - 2013

Fingerprint

Type 2 Diabetes Mellitus
Meals
Glucagon-Like Peptide 1
Therapeutics
Amino Acid Sequence
Insulin
Incretins
Glucagon-Like Peptide-1 Receptor
ZP10A peptide
Metformin
Hypoglycemia
Blood Glucose
Body Weight

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{bc11f53e32f042d3b674dbf4e60a4baf,
title = "Lixisenatid: {\'U}j, d{\"o}ntoen prandialis hat{\'a}s{\'u} GLP-1-receptor-agonista k{\'e}sz{\'i}tm{\'e}ny a 2-es t{\'i}pus{\'u} diabetes kezel{\'e}s{\'e}ben",
abstract = "Recently, lixisenatide, a new incretin mimetic GLP-1-receptor agonist with a mainly prandial effect has been registered for the treatment of patients with type 2 diabetes mellitus. The amino acid sequence of lixisenatide and that of human native GLP-1 is 50{\%} identical. Due to its altered amino acid sequence and conformation, lixisenatide is resistant to inactivation by DPP-4. Lixisenatide is a specific agonist of GLP-1-receptors and its binding has a pharmacologic GLP-1-agonist effect. Lixisenatide is used subcutaneously, its normal daily dose is 1×20 μg. It is mostly used in combination with metformin, but it can be also used to supplement sulfanylurea or basal insulin therapy. Clinical efficiency of lixisenatide has been investigated in the phase-III GetGoal trials. In these trials, adequate glycaemic control and a marked decrease in postprandial blood glucose values were observed. During lixisenatide therapy, a decrease in body weight and no substantial increase in the risk of hypoglycaemia were observed, whereas transient gastrointestinal side effects might occur after initiation of treatment. Lixisenatide as an add-on treatment to basal insulin should be considered as a new treatment approach in the management of type 2 diabetes.",
keywords = "Antidiabetic drugs, Diabetes mellitus, GLP-1, Incretins, Lixisenatide",
author = "G. Jermendy",
year = "2013",
language = "Hungarian",
volume = "23",
pages = "413--419",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "9",

}

TY - JOUR

T1 - Lixisenatid

T2 - Új, döntoen prandialis hatású GLP-1-receptor-agonista készítmény a 2-es típusú diabetes kezelésében

AU - Jermendy, G.

PY - 2013

Y1 - 2013

N2 - Recently, lixisenatide, a new incretin mimetic GLP-1-receptor agonist with a mainly prandial effect has been registered for the treatment of patients with type 2 diabetes mellitus. The amino acid sequence of lixisenatide and that of human native GLP-1 is 50% identical. Due to its altered amino acid sequence and conformation, lixisenatide is resistant to inactivation by DPP-4. Lixisenatide is a specific agonist of GLP-1-receptors and its binding has a pharmacologic GLP-1-agonist effect. Lixisenatide is used subcutaneously, its normal daily dose is 1×20 μg. It is mostly used in combination with metformin, but it can be also used to supplement sulfanylurea or basal insulin therapy. Clinical efficiency of lixisenatide has been investigated in the phase-III GetGoal trials. In these trials, adequate glycaemic control and a marked decrease in postprandial blood glucose values were observed. During lixisenatide therapy, a decrease in body weight and no substantial increase in the risk of hypoglycaemia were observed, whereas transient gastrointestinal side effects might occur after initiation of treatment. Lixisenatide as an add-on treatment to basal insulin should be considered as a new treatment approach in the management of type 2 diabetes.

AB - Recently, lixisenatide, a new incretin mimetic GLP-1-receptor agonist with a mainly prandial effect has been registered for the treatment of patients with type 2 diabetes mellitus. The amino acid sequence of lixisenatide and that of human native GLP-1 is 50% identical. Due to its altered amino acid sequence and conformation, lixisenatide is resistant to inactivation by DPP-4. Lixisenatide is a specific agonist of GLP-1-receptors and its binding has a pharmacologic GLP-1-agonist effect. Lixisenatide is used subcutaneously, its normal daily dose is 1×20 μg. It is mostly used in combination with metformin, but it can be also used to supplement sulfanylurea or basal insulin therapy. Clinical efficiency of lixisenatide has been investigated in the phase-III GetGoal trials. In these trials, adequate glycaemic control and a marked decrease in postprandial blood glucose values were observed. During lixisenatide therapy, a decrease in body weight and no substantial increase in the risk of hypoglycaemia were observed, whereas transient gastrointestinal side effects might occur after initiation of treatment. Lixisenatide as an add-on treatment to basal insulin should be considered as a new treatment approach in the management of type 2 diabetes.

KW - Antidiabetic drugs

KW - Diabetes mellitus

KW - GLP-1

KW - Incretins

KW - Lixisenatide

UR - http://www.scopus.com/inward/record.url?scp=84890539624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890539624&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84890539624

VL - 23

SP - 413

EP - 419

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 9

ER -